MEP3808A - Derivati pirimidinil aril uree kao fgf inhibitori - Google Patents
Derivati pirimidinil aril uree kao fgf inhibitoriInfo
- Publication number
- MEP3808A MEP3808A MEP-38/08A MEP3808A MEP3808A ME P3808 A MEP3808 A ME P3808A ME P3808 A MEP3808 A ME P3808A ME P3808 A MEP3808 A ME P3808A
- Authority
- ME
- Montenegro
- Prior art keywords
- urea derivatives
- aryl urea
- fgf inhibitors
- pyrimidinyl
- pyrimidinyl aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75271105P | 2005-12-21 | 2005-12-21 | |
| PCT/EP2006/070046 WO2007071752A2 (en) | 2005-12-21 | 2006-12-20 | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP3808A true MEP3808A (xx) | 2010-02-10 |
Family
ID=37946774
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-38A ME00011A (me) | 2005-12-21 | 2006-12-20 | Derivati pirimidinilaril uree kao fgf inhibitori |
| MEP-38/08A MEP3808A (xx) | 2005-12-21 | 2006-12-20 | Derivati pirimidinil aril uree kao fgf inhibitori |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-38A ME00011A (me) | 2005-12-21 | 2006-12-20 | Derivati pirimidinilaril uree kao fgf inhibitori |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8293746B2 (xx) |
| EP (1) | EP1976847B1 (xx) |
| JP (1) | JP5153645B2 (xx) |
| KR (1) | KR101406956B1 (xx) |
| CN (1) | CN101336237B (xx) |
| AU (1) | AU2006326989B2 (xx) |
| BR (1) | BRPI0620408B8 (xx) |
| CA (1) | CA2634047C (xx) |
| CR (1) | CR10072A (xx) |
| EA (1) | EA016438B1 (xx) |
| EC (1) | ECSP088561A (xx) |
| GE (1) | GEP20105074B (xx) |
| HN (1) | HN2008000949A (xx) |
| IL (1) | IL192093A0 (xx) |
| MA (1) | MA30063B1 (xx) |
| ME (2) | ME00011A (xx) |
| NO (1) | NO20083214L (xx) |
| SM (1) | SMP200800041B (xx) |
| SV (1) | SV2008002967A (xx) |
| TN (1) | TNSN08276A1 (xx) |
| WO (1) | WO2007071752A2 (xx) |
| ZA (1) | ZA200805092B (xx) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| SMP200800041B (it) * | 2005-12-21 | 2009-07-14 | Novartis Ag | Derivati di pirimidinil-aril-urea attivi come-fgf-inibitori |
| CA2772575A1 (en) * | 2009-08-28 | 2011-03-03 | Genentech, Inc. | Raf inhibitor compounds and methods of use thereof |
| CN102596916B (zh) * | 2009-10-30 | 2015-06-17 | 诺瓦提斯公司 | 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲的n-氧化物 |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| EP2512476A1 (en) * | 2009-12-18 | 2012-10-24 | Novartis AG | Method for treating haematological cancers |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| JP5343177B1 (ja) | 2012-02-28 | 2013-11-13 | アステラス製薬株式会社 | 含窒素芳香族へテロ環化合物 |
| GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
| LT3495367T (lt) | 2012-06-13 | 2021-02-25 | Incyte Holdings Corporation | Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai |
| US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| CN104619326A (zh) * | 2013-03-10 | 2015-05-13 | 国立大学法人名古屋大学 | 骨系统疾病治疗药及其用途 |
| KR20150129847A (ko) | 2013-03-15 | 2015-11-20 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | 융합 단백질 및 이들의 방법 |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| KR102350704B1 (ko) | 2013-03-15 | 2022-01-13 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
| EA036160B1 (ru) | 2013-03-15 | 2020-10-08 | Селджен Кар Ллс | Гетероарильные соединения и их применение |
| EP2789619A1 (en) | 2013-04-12 | 2014-10-15 | Kemotech S.r.l. | Pharmaceutical compounds wiht angiogenesis inbhibitory activity |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2015006492A1 (en) * | 2013-07-09 | 2015-01-15 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| PT3057943T (pt) * | 2013-10-18 | 2018-07-24 | Eisai R&D Man Co Ltd | Inibidores de fgfr4 pirimidina |
| MX367723B (es) * | 2013-10-25 | 2019-09-03 | Novartis Ag | Compuestos de anillos fusionados bicíclicos derivados de piridilo como inhibidores de fgfr4. |
| AR098716A1 (es) | 2013-12-13 | 2016-06-08 | Novartis Ag | Formas de dosificación farmacéuticas |
| EP3171874B1 (en) | 2014-07-21 | 2020-11-18 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| WO2016014551A1 (en) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Macrocyclic kinase inhibitors and uses thereof |
| WO2016023014A2 (en) * | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (sik) inhibitors |
| CN106660997B (zh) | 2014-08-18 | 2019-05-21 | 卫材R&D管理有限公司 | 单环吡啶衍生物的盐及其晶体 |
| US20180185341A1 (en) | 2014-10-03 | 2018-07-05 | Novartis Ag | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| EP3778644A3 (en) | 2014-12-23 | 2021-06-02 | The Trustees of Columbia University in the City of New York | Fgfr-tacc fusion proteins and methods thereof |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134320A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| AU2016248056B2 (en) | 2015-04-14 | 2020-07-23 | Eisai R&D Management Co., Ltd. | Crystalline FGFR4 inhibitor compound and uses thereof |
| CN104803925B (zh) * | 2015-04-16 | 2018-01-12 | 温州医科大学 | 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途 |
| EP3324970A4 (en) * | 2015-07-20 | 2019-03-06 | Taipei Medical University | CHLORINE-SUBSTITUTED AZAARYL COMPOUNDS |
| WO2017118438A1 (zh) * | 2016-01-08 | 2017-07-13 | 杭州英创医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
| EP3454898B1 (en) | 2016-05-10 | 2021-11-10 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
| EP3481830B1 (en) | 2016-07-05 | 2022-02-16 | The Broad Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| WO2018053373A1 (en) | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis |
| EP3555070B1 (en) * | 2016-12-19 | 2023-08-09 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
| RU2019129727A (ru) | 2017-02-28 | 2021-03-30 | Зэ Дженерал Хоспитал Корпорэйшн | Применения пиримидопиримидинонов в качестве ингибиторов sik |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US11219619B2 (en) | 2018-03-28 | 2022-01-11 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
| EP3788046A1 (en) | 2018-05-04 | 2021-03-10 | Incyte Corporation | Salts of an fgfr inhibitor |
| MA52494A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation |
| CN109053593B (zh) * | 2018-08-07 | 2020-12-04 | 温州医科大学 | 1-(2,6-氯苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用 |
| CN109053592B (zh) * | 2018-08-07 | 2020-12-04 | 温州医科大学 | 1-(2,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用 |
| CN109053594B (zh) * | 2018-08-07 | 2020-12-18 | 温州医科大学 | 1-(3,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| CN110283130B (zh) * | 2019-07-05 | 2023-12-19 | 温州医科大学 | 一种1-(2,5-二甲氧基苯基)-3-取代脲类结肠癌抑制剂及其制备和应用 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4045151A1 (en) | 2019-10-14 | 2022-08-24 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3759921A (en) | 1969-10-16 | 1973-09-18 | Lilly Co Eli | Method of suppressing immuneresponse with 1 substituted-3-(2 pyrimidyl)ureas |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| DE60039059D1 (de) | 1999-10-07 | 2008-07-10 | Amgen Inc | Triazin-kinase-hemmer |
| JP3712393B2 (ja) * | 2000-10-20 | 2005-11-02 | エーザイ株式会社 | 含窒素芳香環誘導体 |
| UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| ITMI20010528A1 (it) | 2001-03-13 | 2002-09-13 | Istituto Biochimico Pavese Pha | Complessi di resveratrolo con fosfolipidi loro preparazione e composizioni farmaceutiche e cosmetiche |
| US20020156257A1 (en) | 2001-03-29 | 2002-10-24 | Chunhua Yan | Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof |
| GB0201508D0 (en) * | 2002-01-23 | 2002-03-13 | Novartis Ag | Organic compounds |
| WO2003101444A1 (en) | 2002-05-29 | 2003-12-11 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| US20040034038A1 (en) | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
| AU2003299750A1 (en) | 2002-12-20 | 2004-07-22 | Irm Llc | Differential tumor cytotoxocity compounds and compositions |
| US20060004005A1 (en) | 2003-09-25 | 2006-01-05 | Sattigeri Viswajanani J | Triazines derivatives as cell adhesion inhibitors |
| JP2007515400A (ja) | 2003-11-28 | 2007-06-14 | ノバルティス アクチエンゲゼルシャフト | タンパク質キナーゼ依存性疾患の処置におけるジアリール尿素誘導体 |
| JP2007538063A (ja) | 2004-05-20 | 2007-12-27 | スージェン， インク． | チオフェンヘテロアリールアミン |
| UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| WO2006038112A1 (en) | 2004-10-01 | 2006-04-13 | Warner-Lambert Company Llc | Use of kinase inhibitors to promote neochondrogenesis |
| TW200628159A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
| US20070049592A1 (en) * | 2005-08-22 | 2007-03-01 | Geuns-Meyer Stephanie D | Bis-aryl urea compounds and methods of use |
| SMP200800041B (it) * | 2005-12-21 | 2009-07-14 | Novartis Ag | Derivati di pirimidinil-aril-urea attivi come-fgf-inibitori |
| US20090062320A1 (en) | 2007-08-28 | 2009-03-05 | Vito Guagnano | Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor |
-
2006
- 2006-12-20 SM SM200800041T patent/SMP200800041B/it unknown
- 2006-12-20 GE GEAP200610763A patent/GEP20105074B/en unknown
- 2006-12-20 WO PCT/EP2006/070046 patent/WO2007071752A2/en active Application Filing
- 2006-12-20 KR KR1020087017819A patent/KR101406956B1/ko active IP Right Grant
- 2006-12-20 ME MEP-2008-38A patent/ME00011A/me unknown
- 2006-12-20 BR BRPI0620408A patent/BRPI0620408B8/pt active IP Right Grant
- 2006-12-20 EP EP06830765.1A patent/EP1976847B1/en active Active
- 2006-12-20 CN CN200680051955.3A patent/CN101336237B/zh active Active
- 2006-12-20 ME MEP-38/08A patent/MEP3808A/xx unknown
- 2006-12-20 AU AU2006326989A patent/AU2006326989B2/en active Active
- 2006-12-20 US US12/158,873 patent/US8293746B2/en active Active
- 2006-12-20 JP JP2008546461A patent/JP5153645B2/ja active Active
- 2006-12-20 EA EA200801565A patent/EA016438B1/ru not_active IP Right Cessation
- 2006-12-20 CA CA2634047A patent/CA2634047C/en active Active
-
2008
- 2008-06-11 ZA ZA200805092A patent/ZA200805092B/xx unknown
- 2008-06-12 IL IL192093A patent/IL192093A0/en unknown
- 2008-06-13 CR CR10072A patent/CR10072A/es not_active Application Discontinuation
- 2008-06-18 MA MA31047A patent/MA30063B1/fr unknown
- 2008-06-19 EC EC2008008561A patent/ECSP088561A/es unknown
- 2008-06-20 SV SV2008002967A patent/SV2008002967A/es not_active Application Discontinuation
- 2008-06-20 TN TNP2008000276A patent/TNSN08276A1/en unknown
- 2008-06-20 HN HN2008000949A patent/HN2008000949A/es unknown
- 2008-07-18 NO NO20083214A patent/NO20083214L/no not_active Application Discontinuation
-
2012
- 2012-09-21 US US13/624,320 patent/US8759517B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MEP3808A (xx) | Derivati pirimidinil aril uree kao fgf inhibitori | |
| TN2009000128A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
| JO3007B1 (ar) | مركبات و تركيبات كمثبطات كيناز بروتين | |
| WO2005110994A8 (en) | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | |
| MX2010008719A (es) | Pirrolo [2,-d] piridinas y usos de las mismas como inhibidores de cinasa de tirosina. | |
| TW200724537A (en) | Pyrimidine derivatives for treatment of hyperproliferative disorders | |
| TW200738659A (en) | Novel compounds | |
| NO20090628L (no) | Pyridizinon derivativater | |
| IL177280A (en) | Monohydrate crystal of 2-aminothiazole-5-aromatic carboxamide, process for its preparation, its pharmaceutical composition and its use in the preparation of medicine | |
| ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| MY178660A (en) | Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors | |
| ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
| ATE423105T1 (de) | Triazolonderivate als mmp-inhibitoren zur behandlung von asthma und copd | |
| UA93425C2 (ru) | Производные гидантоина, которые применяются kak mmp ингибиторы | |
| MXPA05010440A (es) | Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b). | |
| WO2009132774A8 (en) | New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors | |
| MX2008001538A (es) | Aril piridinas y metodos para su uso. | |
| MX2009005622A (es) | Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores. | |
| UA90285C2 (ru) | Производные гидантоина, полезные как ингибиторы металлопротеиназ | |
| WO2007076087A3 (en) | 3-aryl-substituted quinazolones, and uses thereof | |
| TW200635916A (en) | Compounds | |
| MX2012015100A (es) | Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina. | |
| MA32183B1 (fr) | Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt | |
| TW200639155A (en) | Thiazolidinones, their production and use as pharmaceutical agents | |
| ATE465165T1 (de) | Pyrimidothienindazole als tyrosinkinasehemmer des epidermalen wachstumsfaktors |